Compare Illumina, Inc. (ILMN) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nerdwallet Inc — how do they compare? Illumina, Inc. trades at $269.34 (market cap $39.95B), while Nerdwallet Inc trades at $9.83 (market cap $625.17M). The key difference: Illumina, Inc. is far larger — about 63.9× Nerdwallet Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Nerdwallet Inc for 45 Days on average.
| ILMN | NRDS | |
|---|---|---|
Market Cap | $39.95B | $625.17M |
Volume | 3,169,503 | 1,321,316 |
Sector | Health | Media |
52-Week High | $293.69 | $15.93 |
52-Week Low | $91.00 | $7.58 |
Typical Hold Time | 83 Days | 45 Days |
Enterprise Value | $41.31B | $539.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
NerdWallet (NRDS) trades at $10.03, up 10.4% in the last session, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with improving fundamentals - revenue grew from $539M in 2022 to $837M in 2025, with net income turning positive since 2024. Recent news highlights the company's Financial Resilience Index publications and Q2 2026 results showing 6% revenue growth despite search pressure in some product categories.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projecting 27.9% upside potential. Key risks include organic search volatility and competitive pressures, but strong cash flow generation and attractive valuation multiples (P/E 10.87, P/S 0.81) support the bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
